NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRK stock has increased by 4.2% and is now trading at $82.54.
View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Friday, July, 31st. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.14 by $0.23. The firm had revenue of $10.87 billion for the quarter, compared to the consensus estimate of $10.52 billion. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 53.61%. Merck & Co., Inc.'s revenue was down 7.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.30 earnings per share.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Wednesday, July 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its board has authorized a share buyback plan on Thursday, October 25th 2018, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 5.1% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its stock is undervalued.

Merck & Co., Inc. issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided earnings per share guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

14 Wall Street analysts have issued 12-month target prices for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $94.93 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

News articles about MRK stock have trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Merck & Co., Inc. earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 14,560,000 shares, a decline of 7.9% from the June 15th total of 15,810,000 shares. Based on an average trading volume of 11,610,000 shares, the short-interest ratio is currently 1.3 days. Currently, 0.6% of the company's stock are short sold.
View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a variety of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.50%), New York State Teachers Retirement System (0.15%), Robeco Institutional Asset Management B.V. (0.14%), Envestnet Asset Management Inc. (0.10%), Raymond James Financial Services Advisors Inc. (0.10%) and Mn Services Vermogensbeheer B.V. (0.09%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Railway Pension Investments Ltd, Robeco Institutional Asset Management B.V., DAVENPORT & Co LLC, Prudential PLC, NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., MERIAN GLOBAL INVESTORS UK Ltd, and Hexavest Inc.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Julie L Gerberding, Richard R Deluca, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc..

MRK stock was bought by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Sumitomo Mitsui Trust Holdings Inc., Alecta Pensionsforsakring Omsesidigt, Candriam Luxembourg S.C.A., Strs Ohio, First Trust Advisors LP, Envestnet Asset Management Inc., and State of Michigan Retirement System.
View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $82.54.

Merck & Co., Inc. has a market capitalization of $208.34 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]